NYSE - Delayed Quote • USD
Pfizer Inc. (PFE)
At close: 4:00 PM EDT
After hours: 4:36 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 23 | 22 |
| Avg. Estimate | 0.53 | 0.45 | 2.21 | 2.72 |
| Low Estimate | 0.37 | 0.35 | 2.05 | 2.22 |
| High Estimate | 0.82 | 0.55 | 2.36 | 3.21 |
| Year Ago EPS | 1.23 | 0.67 | 1.84 | 2.21 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 23 | 22 |
| Avg. Estimate | 14.04B | 13.18B | 60.06B | 62.69B |
| Low Estimate | 12.75B | 12.66B | 58.5B | 58.27B |
| High Estimate | 16.46B | 13.99B | 60.89B | 65.5B |
| Year Ago Sales | 16.59B | 12.73B | 58.5B | 60.06B |
| Sales Growth (year/est) | -15.40% | 3.50% | 2.70% | 4.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.98 | 0.57 | -0.34 | -0.22 |
| EPS Actual | 1.23 | 0.67 | -0.17 | 0.1 |
| Difference | 0.25 | 0.1 | 0.17 | 0.32 |
| Surprise % | 25.50% | 17.50% | 50.00% | 145.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.53 | 0.45 | 2.21 | 2.72 |
| 7 Days Ago | 0.54 | 0.45 | 2.2 | 2.74 |
| 30 Days Ago | 0.54 | 0.45 | 2.2 | 2.74 |
| 60 Days Ago | 0.51 | 0.45 | 2.2 | 2.72 |
| 90 Days Ago | 0.61 | 0.48 | 2.27 | 2.74 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | -- |
| Up Last 30 Days | 4 | 1 | 7 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 2 | 1 | 4 |
Growth Estimates
| CURRENCY IN USD | PFE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -56.90% | -- | -- | 1.60% |
| Next Qtr. | -32.80% | -- | -- | 10.50% |
| Current Year | 20.10% | -- | -- | 5.20% |
| Next Year | 23.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -1.33% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 0.52% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Downgrade | Argus Research: Buy to Hold | 3/22/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/4/2024 |
Related Tickers
JNJ Johnson & Johnson
147.91
+1.49%
BMY Bristol-Myers Squibb Company
48.93
+1.30%
ABBV AbbVie Inc.
166.41
+1.06%
LLY Eli Lilly and Company
726.31
-2.63%
MRK Merck & Co., Inc.
125.78
+0.44%
GILD Gilead Sciences, Inc.
66.76
+0.91%
AMGN Amgen Inc.
268.93
+2.35%
BIIB Biogen Inc.
194.38
+2.03%
GSK GSK plc
39.75
+1.22%
AZN AstraZeneca PLC
68.55
+0.28%